News
FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.
The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.
Amber Specialty Pharmacy, a pioneer in specialty pharmacy for more than 25 years, today announced it is now dispensing ...
Pharmaceutical Technology on MSN3d
Insmed wins FDA approval for future blockbuster Brinsupri
Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed ...
Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...
With a landmark U.S. approval Tuesday, Insmed is making waves with a new class of drug that’s also the first to be green lit in the chronic lung disease bronchiectasis. | The FDA on Tuesday signed ...
Investor's Business Daily on MSN4d
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval
Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a devastating lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback